EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors Influencing the Effectiveness of Botulinum Toxin Therapy in Bruxism Management

Azusa Furuhata iD, Kazuya Yoshida iD, Shiroh Isono iD

Toxins · 2025

DOI: 10.3390/toxins17080384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Azusa Furuhata und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Nippon Dental University, Tokyo 102-8158, Japan. Hauptthemen laut MEDLINE: Bruxism, Masseter Muscle, Neuromuscular Agents, Botulinum Toxins, Type A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A total of 304 patients with bruxism (206 women, 98 men; mean age: 52.5 years) received 25 units of botulinum toxin injected into the bilateral masseter muscles; the changes in various clinical symptoms and their contributing factors were analyzed 2 months after treatment. The mean masseter muscle electromyographic amplitude (189 μV) and maximal bite force (618.4 N) significantly decreased after botulinum toxin therapy compared to that at baseline (55.4 μV, 527.3 N, respectively; p < 0.001). Maximal mouth opening (44 mm), sleep quality (visual analog scale: 5.3), shoulder and neck stiffness (6.7), and headache (5.4) significantly improved after the injection (47.3 mm, 6.6, 4.7, and 2.6, respectively; p < 0.001). Multivariate analysis revealed that the mean masseter electromyographic amplitude reduction rate was significantly affected by age, sex, and baseline amplitude (all p < 0.001); the maximal bite force reduction rate was influenced by age (p < 0.001), sex (p = 0.007), and baseline bite force (p = 0.008). Age, sex, and muscle activity may affect the therapeutic effects. A more effective outcome for bruxism can be achieved using a tailored approach involving dose adjustment, thereby preventing the side effects attributed to excessive dosage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BruxismMasseter MuscleNeuromuscular AgentsBotulinum Toxins, Type ABotulinum ToxinsHumansFemaleMaleMiddle AgedAdultElectromyographyAgedTreatment OutcomeYoung AdultBite Force

Stichwörter der Autor:innen

agingbite forcebotulinum neurotoxinbotulinum toxin therapybruxismelectromyographymasseter musclemuscle painsex differencesleep quality

Substanzen

Neuromuscular AgentsBotulinum Toxins, Type ABotulinum Toxins

Autor:innen und Institutionen

  • Department of Internal Medicine, Nippon Dental University, Tokyo 102-8158, Japan.
  • Furuhata Snoring and Sleep Disorder Research Institute and Furuhata Dental Clinic, Tokyo 107-0052, Japan.
  • Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan.
  • Department of Anesthesiology, Chiba University, Chiba 260-8677, Japan.

ORCID-Profile: Azusa Furuhata, Kazuya Yoshida, Shiroh Isono

Zitieren

APA

Furuhata, A., Yoshida, K., & Isono, S. (2025). Factors Influencing the Effectiveness of Botulinum Toxin Therapy in Bruxism Management. Toxins. https://doi.org/10.3390/toxins17080384

Vancouver

Furuhata A, Yoshida K, Isono S. Factors Influencing the Effectiveness of Botulinum Toxin Therapy in Bruxism Management. Toxins. 2025. doi:10.3390/toxins17080384

BibTeX
@article{Furuhata2025,
  author = {Furuhata, Azusa and Yoshida, Kazuya and Isono, Shiroh},
  title = {Factors Influencing the Effectiveness of Botulinum Toxin Therapy in Bruxism Management},
  journal = {Toxins},
  year = {2025},
  doi = {10.3390/toxins17080384}
}
Kostenlos starten →